Abstract | AIM: METHODS: RESULTS: In multivariable analysis, in which we corrected for allocated treatment and other baseline characteristics, elevated pretreatment CEA (HR 1.43; 95% CI 1.11-1.85, p < 0.001) and CA 19-9 (HR 1.79; 95% CI 1.42-2.25, p < 0.001) were associated with worse OS. Likelihoods to receive potentially curative surgery were 86%, 77% and 60% for patients without elevated tumor marker versus either elevated CEA or CA 19-9 versus both elevated, respectively (p < 0.001). Although both preoperative presence of ctDNA and tumor markers were prognostic for survival, no association was found between these two parameters. CONCLUSION: CEA and CA 19-9 were independent prognostic factors for survival in a large cohort of European patients with resectable gastric cancer. No relationship was found between tumor markers and ctDNA. These factors could potentially guide treatment choices and should be included in future trials to determine their definitive position. TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT00407186. EudraCT number: 2006-00413032.
|
Authors | Astrid E Slagter, Marieke A Vollebergh, Irene A Caspers, Johanna W van Sandick, Karolina Sikorska, Pehr Lind, Marianne Nordsmark, Hein Putter, Jeffrey P B M Braak, Elma Meershoek-Klein Kranenbarg, Cornelis J H van de Velde, Edwin P M Jansen, Annemieke Cats, Hanneke W M van Laarhoven, Nicole C T van Grieken, Marcel Verheij |
Journal | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
(Gastric Cancer)
Vol. 25
Issue 2
Pg. 401-410
(Mar 2022)
ISSN: 1436-3305 [Electronic] Japan |
PMID | 34714423
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | © 2021. The Author(s). |
Chemical References |
- Biomarkers, Tumor
- Circulating Tumor DNA
|
Topics |
- Biomarkers, Tumor
(genetics)
- Circulating Tumor DNA
(genetics)
- Humans
- Prognosis
- Stomach Neoplasms
(genetics, surgery)
|